

Chris J L M Meijer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3716592/publications.pdf>

Version: 2024-02-01

280
papers

41,396
citations

6613

79
h-index

2385

198
g-index

282
all docs

282
docs citations

282
times ranked

20912
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>FAM19A4/miR124-2</i> Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years. <i>Clinical Infectious Diseases</i> , 2023, 76, e827-e834.	5.8	4
2	Performance of <i>DNA</i> methylation analysis of <i>ASCL1</i> , <i>LHX8</i> , <i>ST6GALNAC5</i> , <i>GHSR</i> , <i>ZIC1</i> and <i>SST</i> for the triage of HPV-positive women: Results from a Dutch primary HPV-based screening cohort. <i>International Journal of Cancer</i> , 2022, 150, 440-449.	5.1	17
3	Direct bisulphite conversion of cervical samples for DNA methylation analysis. <i>Epigenetics</i> , 2022, 17, 1173-1179.	2.7	6
4	Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping. <i>British Journal of Cancer</i> , 2022, 126, 259-264.	6.4	13
5	Post-treatment monitoring by ASCL1/LHX8 methylation analysis in women with HIV treated for cervical intraepithelial neoplasia grade 2/3. <i>Aids</i> , 2022, Publish Ahead of Print, .	2.2	1
6	Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening. <i>Viruses</i> , 2022, 14, 893.	3.3	1
7	Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of <i>FAM19A4/miR124-2</i> DNA Methylation (CONCERVE Study). <i>Journal of Clinical Oncology</i> , 2022, 40, 3037-3046.	1.6	25
8	Women with a positive high-risk human papillomavirus (HPV) test remain at increased risk of HPV infection and cervical precancer 15 years later. <i>Tumour Virus Research</i> , 2022, 14, 200240.	3.8	2
9	Cancer Risk Stratification of Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-Positive Men by Validated Methylation Markers Associated With Progression to Cancer. <i>Clinical Infectious Diseases</i> , 2021, 72, 2154-2163.	5.8	36
10	Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer. <i>International Journal of Cancer</i> , 2021, 148, 320-328.	5.1	7
11	Methylation markers <i>FAM19A4</i> and <i>miR124-2</i> as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study. <i>International Journal of Cancer</i> , 2021, 148, 396-405.	5.1	56
12	Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse in HPV-Positive Women with Normal Cytology and Five-Year Type Concordance: A Randomized Comparison. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 485-491.	2.5	0
13	Impact of Collection Volume and DNA Extraction Method on the Detection of Biomarkers and HPV DNA in First-Void Urine. <i>Molecules</i> , 2021, 26, 1989.	3.8	10
14	Male Circumcision Reduces Penile HPV Incidence and Persistence: A Randomized Controlled Trial in Kenya. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1139-1148.	2.5	12
15	Classification of high-grade cervical intraepithelial neoplasia by p16 ^{ink4a} , Ki67, HPV E4 and <i>FAM19A4/miR124-2</i> methylation status demonstrates considerable heterogeneity with potential consequences for management. <i>International Journal of Cancer</i> , 2021, 149, 707-716.	5.1	26
16	Characterisation of anal intraepithelial neoplasia and anal cancer in HIV-positive men by immunohistochemical markers p16, Ki67, HPV E4 and <i>DNA</i> methylation markers. <i>International Journal of Cancer</i> , 2021, 149, 1833-1844.	5.1	6
17	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1083-1095.	6.0	116
18	<i>FAM19A4/miR124-2</i> methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. <i>International Journal of Cancer</i> , 2020, 147, 1215-1221.	5.1	40

#	ARTICLE	IF	CITATIONS
19	Developing and Standardizing Human Papillomavirus Tests. , 2020, , 111-130.		3
20	Primary Screening by Human Papillomavirus Testing: Development, Implementation, and Perspectives. , 2020, , 245-268.		0
21	Infection to Cancerâ€”Finding Useful Biomarkers for Predicting Risk of Progression to Cancer. , 2020, , 269-282.		1
22	Incidence and clearance of penile human papillomavirus infection among circumcised Kenyan men. International Journal of STD and AIDS, 2020, 31, 1202-1211.	1.1	0
23	Evaluation of six methylation markers derived from genome-wide screens for detection of cervical precancer and cancer. Epigenomics, 2020, 12, 1569-1578.	2.1	15
24	Expression of p16 and HPV E4 on biopsy samples and methylation of FAM19A4 and miR124â€”2 on cervical cytology samples in the classification of cervical squamous intraepithelial lesions. Cancer Medicine, 2020, 9, 2454-2461.	2.8	13
25	Characterization of cervical biopsies of women with HIV and HPV co-infection using p16ink4a, ki-67 and HPV E4 immunohistochemistry and DNA methylation. Modern Pathology, 2020, 33, 1968-1978.	5.5	6
26	Host Cell Deoxyribonucleic Acid Methylation Markers for the Detection of High-grade Anal Intraepithelial Neoplasia and Anal Cancer. Clinical Infectious Diseases, 2019, 68, 1110-1117.	5.8	25
27	Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytologyâ€”screened referral population. International Journal of Cancer, 2019, 144, 160-168.	5.1	15
28	HPV infections and flat penile lesions of the penis in men who have sex with men. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100173.	4.5	5
29	Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands. Preventive Medicine, 2019, 125, 5-11.	3.4	48
30	Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. Gynecologic Oncology, 2019, 154, 368-373.	1.4	32
31	HPV16 variant analysis in primary and recurrent CIN2/3 lesions demonstrates presence of the same consensus variant. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 168-172.	4.5	6
32	Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females. PLoS ONE, 2019, 14, e0212927.	2.5	15
33	Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease. Epigenetics, 2019, 14, 558-567.	2.7	7
34	Role of<i>FAM19A4</i>/<i>miR124-2</i> methylation analysis in predicting regression or non-regression of CIN2/3 lesions: a protocol of an observational longitudinal cohort study. BMJ Open, 2019, 9, e029017.	1.9	12
35	The use of molecular markers for cervical screening of women living with HIV in South Africa. Aids, 2019, 33, 2035-2042.	2.2	20
36	Genomeâ€”wide microRNA analysis of HPVâ€”positive selfâ€”samples yields novel triage markers for early detection of cervical cancer. International Journal of Cancer, 2019, 144, 372-379.	5.1	29

#	ARTICLE	IF	CITATIONS
37	Management of HPV-positive women in cervical screening using results from two consecutive screening rounds. <i>International Journal of Cancer</i> , 2019, 144, 2339-2346.	5.1	9
38	Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 229-238.	10.7	129
39	Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up. <i>International Journal of Cancer</i> , 2018, 143, 1541-1548.	5.1	63
40	Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples. <i>Clinical Cancer Research</i> , 2018, 24, 3456-3464.	7.0	55
41	Anal HPV 16 and 18 viral load: A comparison between HIV-negative and -positive MSM and association with persistence. <i>Journal of Medical Virology</i> , 2018, 90, 76-83.	5.0	5
42	High Whole-Genome Sequence Diversity of Human Papillomavirus Type 18 Isolates. <i>Viruses</i> , 2018, 10, 68.	3.3	14
43	HPV16-Related Cervical Cancers and Precancers Have Increased Levels of Host Cell DNA Methylation in Women Living with HIV. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3297.	4.1	7
44	Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation. <i>Gynecologic Oncology</i> , 2018, 151, 311-318.	1.4	7
45	Detection of hypermethylated genes as markers for cervical screening in women living with HIV. <i>Journal of the International AIDS Society</i> , 2018, 21, e25165.	3.0	18
46	Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer. <i>Epigenetics</i> , 2018, 13, 769-778.	2.7	43
47	Three-tiered score for Ki-67 and p16 ^{ink4a} improves accuracy and reproducibility of grading CIN lesions. <i>Journal of Clinical Pathology</i> , 2018, 71, 981-988.	2.0	33
48	Triage of high-risk HPV-positive women in population-based screening by miRNA expression analysis in cervical scrapes; a feasibility study. <i>Clinical Epigenetics</i> , 2018, 10, 76.	4.1	18
49	Molecular heterogeneity in human papillomavirus-dependent and -independent vulvar carcinogenesis. <i>Cancer Medicine</i> , 2018, 7, 4542-4553.	2.8	21
50	HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions. <i>Modern Pathology</i> , 2018, 31, 1842-1850.	5.5	37
51	Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3813-3822.	7.0	68
52	Novel molecular subtypes of cervical cancer – potential clinical consequences. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 397-398.	27.6	18
53	Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women. <i>Modern Pathology</i> , 2017, 30, 1021-1031.	5.5	49
54	HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test. <i>British Journal of Cancer</i> , 2017, 117, 1557-1561.	6.4	28

#	ARTICLE	IF	CITATIONS
55	Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening. <i>International Journal of Cancer</i> , 2017, 141, 1551-1560.	5.1	7
56	Human Papillomavirus Triage of Women With Atypical Squamous Cells of Undetermined Significance—Reduction of Overtreatment Needed. <i>JAMA Oncology</i> , 2017, 3, 1310.	7.1	5
57	Selection of women at risk for cervical cancer in an HIV-infected South African population. <i>Aids</i> , 2017, 31, 1945-1953.	2.2	17
58	Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN. <i>International Journal of Cancer</i> , 2017, 140, 423-430.	5.1	16
59	Whole-Genome Sequencing and Variant Analysis of Human Papillomavirus 16 Infections. <i>Journal of Virology</i> , 2017, 91, .	3.4	33
60	CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies. <i>International Journal of Cancer</i> , 2016, 138, 463-471.	5.1	35
61	Validation of the FAM19A4 / mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. <i>Gynecologic Oncology</i> , 2016, 141, 341-347.	1.4	80
62	p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. <i>Modern Pathology</i> , 2016, 29, 870-878.	5.5	43
63	Management of high-risk HPV-positive women for detection of cervical (pre)cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 961-974.	3.1	45
64	FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. <i>British Journal of Cancer</i> , 2016, 115, 579-587.	6.4	55
65	Correlation between viral load, multiplicity of infection, and persistence of HPV16 and HPV18 infection in a Dutch cohort of young women. <i>Journal of Clinical Virology</i> , 2016, 83, 6-11.	3.1	40
66	A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. <i>Vaccine</i> , 2016, 34, 4205-4212.	3.8	68
67	Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. <i>BMJ, The</i> , 2016, 355, i4924.	6.0	86
68	Higher HPV16 and HPV18 Penile Viral Loads Are Associated With Decreased Human Papillomavirus Clearance in Uncircumcised Kenyan Men. <i>Sexually Transmitted Diseases</i> , 2016, 43, 572-578.	1.7	6
69	Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study). <i>International Journal of Cancer</i> , 2016, 138, 992-1002.	5.1	60
70	The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples. <i>International Journal of Cancer</i> , 2016, 139, 691-699.	5.1	23
71	Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion. <i>Cancer Cytopathology</i> , 2016, 124, 66-67.	2.4	10
72	Presence of human papillomavirus in semen in relation to semen quality. <i>Human Reproduction</i> , 2016, 31, dev317.	0.9	39

#	ARTICLE	IF	CITATIONS
73	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 119-132.	27.6	154
74	Immortalization capacity of HPV types is inversely related to chromosomal instability. <i>Oncotarget</i> , 2016, 7, 37608-37621.	1.8	25
75	Aberrant methylation-mediated silencing of microRNAs contributes to HPV-induced anchorage independence. <i>Oncotarget</i> , 2016, 7, 43805-43819.	1.8	22
76	ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. <i>Haematologica</i> , 2015, 100, e365-e368.	3.5	5
77	Methylation Levels of CADM1, MAL, and MIR124-2 in Cervical Scrapes for Triage of HIV-Infected, High-Risk HPV-Positive Women in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 311-318.	2.1	33
78	Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?. <i>International Journal of Cancer</i> , 2015, 137, 420-427.	5.1	21
79	Longitudinal assessment of DNA methylation changes during HPV E6/E7-induced immortalization of primary keratinocytes. <i>Epigenetics</i> , 2015, 10, 73-81.	2.7	29
80	Triaging HPV-positive women with normal cytology by p16/Ki67 dual-stained cytology testing: Baseline and longitudinal data. <i>International Journal of Cancer</i> , 2015, 136, 2361-2368.	5.1	61
81	Presence of human papillomavirus in semen of healthy men is firmly associated with HPV infections of the penile epithelium. <i>Fertility and Sterility</i> , 2015, 104, 838-844.e8.	1.0	20
82	Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes. <i>Gynecologic Oncology</i> , 2015, 137, 55-59.	1.4	22
83	Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women. <i>Journal of Clinical Virology</i> , 2015, 67, 59-66.	3.1	20
84	The Age Distribution of Type-Specific High-Risk Human Papillomavirus Incidence in Two Population-Based Screening Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 111-118.	2.5	11
85	Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing. <i>Cancer Prevention Research</i> , 2015, 8, 502-508.	1.5	24
86	Acquisition and Persistence of Human Papillomavirus 16 (HPV-16) and HPV-18 Among Men With High-HPV Viral Load Infections in a Circumcision Trial in Kisumu, Kenya. <i>Journal of Infectious Diseases</i> , 2015, 211, 811-820.	4.0	21
87	Combined CADM1/MAL Methylation and Cytology Testing for Colposcopy Triage of High-Risk HPV-Positive Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1933-1937.	2.5	39
88	Methylation-mediated repression of PRDM14 contributes to apoptosis evasion in HPV-positive cancers. <i>Carcinogenesis</i> , 2014, 35, 2611-2618.	2.8	35
89	Arguments in favor of HPV testing for cervical screening and post-treatment CIN2+ monitoring. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 245-248.	3.1	4
90	CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. <i>Journal of Clinical Pathology</i> , 2014, 67, 1067-1071.	2.0	82

#	ARTICLE	IF	CITATIONS
91	Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. <i>International Journal of Cancer</i> , 2014, 135, 1408-1416.	5.1	33
92	Twelve-month incidence and clearance of oral HPV infection in HIV-negative and HIV-infected men who have sex with men: the H2M cohort study. <i>BMC Infectious Diseases</i> , 2014, 14, 668.	2.9	19
93	Posttreatment Assessment of Women at Risk of Developing High-Grade Cervical Disease. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, 338-343.	1.9	15
94	Differential <i>In Vitro</i> Immortalization Capacity of Eleven, Probable High-Risk Human Papillomavirus Types. <i>Journal of Virology</i> , 2014, 88, 1714-1724.	3.4	27
95	Primary hrHPV DNA Testing in Cervical Cancer Screening: How to Manage Screen-Positive Women? A POBASCAM Trial Substudy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 55-63.	2.5	82
96	Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in Dutch women. <i>Preventive Medicine</i> , 2014, 64, 108-113.	3.4	70
97	Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. <i>Nature Reviews Cancer</i> , 2014, 14, 395-405.	28.4	295
98	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. <i>Lancet</i> , The, 2014, 383, 524-532.	13.7	1,282
99	Methylation Analysis of the <i>FAM19A4</i> Gene in Cervical Scrapes Is Highly Efficient in Detecting Cervical Carcinomas and Advanced CIN2/3 Lesions. <i>Cancer Prevention Research</i> , 2014, 7, 1251-1257.	1.5	97
100	Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer. <i>Gynecologic Oncology</i> , 2014, 135, 58-63.	1.4	45
101	Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROTECT-3): a randomised controlled non-inferiority trial. <i>Lancet Oncology</i> , The, 2014, 15, 315-322.	10.7	147
102	Six-Month Incidence and Persistence of Oral HPV Infection in HIV-Negative and HIV-Infected Men Who Have Sex with Men. <i>PLoS ONE</i> , 2014, 9, e98955.	2.5	23
103	Imbalance in Alternative Splicing of MCL-1 Inhibits Apoptosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 5424-5424.	1.4	0
104	Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis. <i>Journal of Pathology</i> , 2013, 231, 53-62.	4.5	48
105	Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. <i>International Journal of Cancer</i> , 2013, 132, 1565-1571.	5.1	177
106	<i>CADM1</i> and <i>MAL</i> promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. <i>International Journal of Cancer</i> , 2013, 133, 1293-1299.	5.1	100
107	Differential presence of Papillomavirus variants in cervical cancer: An analysis for HPV33, HPV45 and HPV58. <i>Infection, Genetics and Evolution</i> , 2013, 13, 96-104.	2.3	17
108	Focal aberrations indicate <i>EYA2</i> and <i>hsa-miR-375</i> as oncogene and tumor suppressor in cervical carcinogenesis. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 56-68.	2.8	76

#	ARTICLE	IF	CITATIONS
109	High-risk HPV testing on self-sampled versus clinician-collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. <i>International Journal of Cancer</i> , 2013, 132, 2223-2236.	5.1	210
110	Clinical Progression of High-Grade Cervical Intraepithelial Neoplasia: Estimating the Time to Preclinical Cervical Cancer From Doubly Censored National Registry Data. <i>American Journal of Epidemiology</i> , 2013, 178, 1161-1169.	3.4	100
111	Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. <i>Epigenetics</i> , 2013, 8, 220-228.	2.7	67
112	Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. <i>Aids</i> , 2013, 27, 2921-2931.	2.2	80
113	Oral human papillomavirus infection in HIV-negative and HIV-infected MSM. <i>Aids</i> , 2013, 27, 2117-2128.	2.2	56
114	Follow-up after treatment for cervical intraepithelial neoplasia. <i>BMJ</i> , The, 2012, 345, e7186-e7186.	6.0	5
115	Comprehensive analysis of human papillomavirus prevalence and the potential role of low-risk types in verrucous carcinoma. <i>Modern Pathology</i> , 2012, 25, 1354-1363.	5.5	66
116	Cervical cancer—should we abandon cytology for screening?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 558-559.	27.6	5
117	Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer. <i>Vaccine</i> , 2012, 30, F88-F99.	3.8	695
118	Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 78-88.	10.7	431
119	Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: High concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN. <i>Journal of Clinical Virology</i> , 2012, 54, 147-151.	3.1	40
120	Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders. <i>European Journal of Cancer</i> , 2012, 48, 1799-1808.	2.8	66
121	Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. <i>BMC Cancer</i> , 2012, 12, 551.	2.6	54
122	New Technologies and Procedures for Cervical Cancer Screening. <i>Vaccine</i> , 2012, 30, F107-F116.	3.8	117
123	Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. <i>International Journal of Cancer</i> , 2012, 131, 949-955.	5.1	62
124	Chromosomal profiles of high-grade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. <i>International Journal of Cancer</i> , 2012, 131, E579-85.	5.1	37
125	Methylation status of the E2 binding sites of HPV16 in cervical lesions determined with the Luminex [®] xMAP [®] system. <i>Virology</i> , 2012, 422, 357-365.	2.4	30
126	High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2012, 125, 500-507.	1.4	97

#	ARTICLE	IF	CITATIONS
127	HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia. BMC Cancer, 2012, 12, 36.	2.6	10
128	Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. International Journal of Cancer, 2012, 130, 602-610.	5.1	179
129	Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. International Journal of Cancer, 2012, 130, 1128-1135.	5.1	101
130	Male circumcision is associated with a lower prevalence of human papillomavirus-associated penile lesions among Kenyan men. International Journal of Cancer, 2012, 130, 1888-1897.	5.1	51
131	Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncology, The, 2011, 12, 441-450.	10.7	182
132	A new approach to cervical screening. Lancet Oncology, The, 2011, 12, 612-613.	10.7	3
133	Long-term Impact of Human Papillomavirus Vaccination on Infection Rates, Cervical Abnormalities, and Cancer Incidence. Epidemiology, 2011, 22, 505-515.	2.7	62
134	High-risk human papillomavirus seems not involved in DES-related and of limited importance in nonDES related clear-cell carcinoma of the cervix. Gynecologic Oncology, 2011, 122, 297-302.	1.4	19
135	PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Molecular Cancer, 2011, 10, 71.	19.2	47
136	Human papillomavirus infection in a population-based sample of women in Algiers, Algeria. International Journal of Cancer, 2011, 128, 2224-2229.	5.1	29
137	Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. International Journal of Cancer, 2011, 129, 2218-2225.	5.1	87
138	Combined Promoter Methylation Analysis of CADM1 and MAL: An Objective Triage Tool for High-Risk Human Papillomavirus DNA-Positive Women. Clinical Cancer Research, 2011, 17, 2459-2465.	7.0	119
139	Molecular Biology of Penile Cancer. , 2011, , 13-25.		1
140	hsTRAIL/Apo2L Induces Apoptosis in Enteropathy-Associated T-Cell Lymphoma. Blood, 2011, 118, 1665-1665.	1.4	0
141	Bortezomib Restores Defective Apoptosis by Upregulation of Noxa in Enteropathy-Associated T-Cell Lymphoma. Blood, 2011, 118, 2722-2722.	1.4	0
142	Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). International Journal of Cancer, 2010, 126, 2175-2181.	5.1	15
143	HPV Screening: Available Data and Recommendations for Clinical Practice. Current Cancer Therapy Reviews, 2010, 6, 104-109.	0.3	4
144	Colposcopic Characteristics of High-Risk Human Papillomavirus-Related Cervical Lesions. Journal of Lower Genital Tract Disease, 2010, 14, 49-55.	1.9	3

#	ARTICLE	IF	CITATIONS
145	hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer, 2010, 10, 271.	2.6	53
146	Prevalence and risk factors of human papillomavirus infection by penile site in uncircumcised Kenyan men. International Journal of Cancer, 2010, 126, 572-577.	5.1	37
147	Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. Journal of Pathology, 2010, 220, 509-520.	4.5	20
148	Methods for HPV detection in exfoliated cell and tissue specimens. Apmis, 2010, 118, 520-528.	2.0	50
149	Increased Risk of HIV Acquisition among Kenyan Men with Human Papillomavirus Infection. Journal of Infectious Diseases, 2010, 201, 1677-1685.	4.0	72
150	HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ: British Medical Journal, 2010, 340, c1040-c1040.	2.3	240
151	Model-Based Estimation of Viral Transmissibility and Infection-Induced Resistance From the Age-Dependent Prevalence of Infection for 14 High-Risk Types of Human Papillomavirus. American Journal of Epidemiology, 2010, 171, 817-825.	3.4	66
152	Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Molecular Cancer, 2010, 9, 167.	19.2	217
153	Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncology, The, 2010, 11, 1048-1056.	10.7	2,093
154	Factors affecting transmission of mucosal human papillomavirus. Lancet Infectious Diseases, The, 2010, 10, 862-874.	9.1	131
155	Promiscuous Behavior of HPV16E6 Specific T Cell Receptor Beta Chains Hampers Functional Expression in TCR Transgenic T Cells, Which Can Be Restored in Part by Genetic Modification. Analytical Cellular Pathology, 2010, 32, 43-56.	1.4	0
156	Bortezomib Induces Caspase-9-Mediated Apoptosis through Activation of the BH3-Only Proteins Noxa, Bik and Puma In Both ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma Cells. Blood, 2010, 116, 2847-2847.	1.4	7
157	Enteropathy-Associated T-Cell Lymphoma: a Clinical Prognostic Model to Identify High Risk Patients. Blood, 2010, 116, 3092-3092.	1.4	0
158	Chromosomal Signatures of a Subset of High-Grade Premalignant Cervical Lesions Closely Resemble Invasive Carcinomas. Cancer Research, 2009, 69, 647-655.	0.9	53
159	Post-treatment CIN: Randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. International Journal of Cancer, 2009, 124, 889-895.	5.1	26
160	High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. International Journal of Cancer, 2009, 124, 381-386.	5.1	59
161	HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model-based cost-effectiveness. International Journal of Cancer, 2009, 124, 970-978.	5.1	39
162	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. International Journal of Cancer, 2009, 124, 516-520.	5.1	557

#	ARTICLE	IF	CITATIONS
163	Human papillomavirus in early laryngeal carcinoma. <i>Laryngoscope</i> , 2009, 119, 1531-1537.	2.0	81
164	Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. <i>Journal of Pathology</i> , 2009, 219, 327-336.	4.5	95
165	Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. <i>BMC Medical Genomics</i> , 2009, 2, 32.	1.5	56
166	Prevention of cervical cancer: Where immunology meets diagnostics. <i>Immunology Letters</i> , 2009, 122, 126-127.	2.5	4
167	Human papilloma virus in head and neck cancer: The need for a standardised assay to assess the full clinical importance. <i>European Journal of Cancer</i> , 2009, 45, 2935-2939.	2.8	77
168	How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. <i>Vaccine</i> , 2009, 27, 5111-5119.	3.8	18
169	Gene expression profiling to identify markers associated with deregulated hTERT in HPV α -transformed keratinocytes and cervical cancer. <i>International Journal of Cancer</i> , 2008, 122, 877-888.	5.1	26
170	Intra α -operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. <i>International Journal of Cancer</i> , 2008, 122, 2562-2567.	5.1	167
171	Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. <i>Vaccine</i> , 2008, 26, F46-F58.	3.8	48
172	Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. <i>Vaccine</i> , 2008, 26, K29-K41.	3.8	526
173	Cervical cancer prevention: who should receive vaccination?. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 12-13.	4.3	2
174	Human Papillomavirus-16 Is the Predominant Type Etiologically Involved in Penile Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4550-4556.	1.6	147
175	Human Papillomavirus Detection by Penile Site in Young Men From Kenya. <i>Sexually Transmitted Diseases</i> , 2007, 34, 928-934.	1.7	29
176	Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. <i>Vaccine</i> , 2007, 25, 6245-6256.	3.8	41
177	HPV Detection Methods. <i>Disease Markers</i> , 2007, 23, 273-281.	1.3	66
178	Human papillomavirus testing on self α -sampled cervicovaginal brushes: An effective alternative to protect nonresponders in cervical screening programs. <i>International Journal of Cancer</i> , 2007, 120, 1505-1510.	5.1	145
179	Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. <i>International Journal of Cancer</i> , 2007, 121, 361-367.	5.1	55
180	CD4 $^{+}$ CD25 hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2007, 121, 1749-1755.	5.1	134

#	ARTICLE	IF	CITATIONS
181	A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. <i>International Journal of Cancer</i> , 2007, 121, 2465-2472.	5.1	658
182	HPV16 and increased risk of recurrence after treatment for CIN. <i>Gynecologic Oncology</i> , 2007, 104, 273-275.	1.4	62
183	Chemotherapy-Refractory Diffuse Large B-Cell Lymphomas (DLBCL) Are Effectively Killed by Ofatumumab-Induced Complement-Mediated Cytotoxicity.. <i>Blood</i> , 2007, 110, 2346-2346.	1.4	5
184	Small-Molecule XIAP Antagonist Restores Caspase-9-Mediated Apoptosis in XIAP-Positive Diffuse Large B-Cell Lymphoma Cells.. <i>Blood</i> , 2007, 110, 803-803.	1.4	2
185	Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. <i>Vaccine</i> , 2006, 24, S78-S89.	3.8	393
186	Molecular Markers for Cervical Cancer. , 2006, , 73-81.		0
187	HPV-mediated cervical carcinogenesis: concepts and clinical implications. <i>Journal of Pathology</i> , 2006, 208, 152-164.	4.5	360
188	HPV testing in cervical screening. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2006, 20, 253-266.	2.8	27
189	Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. <i>International Journal of Cancer</i> , 2006, 118, 1759-1768.	5.1	47
190	A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. <i>International Journal of Cancer</i> , 2006, 118, 791-796.	5.1	60
191	Overview of the European and North American studies on HPV testing in primary cervical cancer screening. <i>International Journal of Cancer</i> , 2006, 119, 1095-1101.	5.1	922
192	Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. <i>International Journal of Cancer</i> , 2006, 119, 1102-1107.	5.1	99
193	Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. <i>International Journal of Cancer</i> , 2006, 119, 1078-1081.	5.1	214
194	Flat penile lesions: The infectious "invisible" link in the transmission of human papillomavirus. <i>International Journal of Cancer</i> , 2006, 119, 2505-2512.	5.1	39
195	Human Papillomavirus Type-Specific 18-Month Risk of High-Grade Cervical Intraepithelial Neoplasia in Women with a Normal or Borderline/Mildly Dyskaryotic Smear. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1268-1273.	2.5	60
196	High Concordance of Results of Testing for Human Papillomavirus in Cervicovaginal Samples Collected by Two Methods, with Comparison of a Novel Self-Sampling Device to a Conventional Endocervical Brush. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2518-2523.	3.9	81
197	Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention. <i>Journal of the National Cancer Institute</i> , 2006, 98, 303-315.	6.3	568
198	HPV-associated flat penile lesions in men of a non-STD hospital population: Less frequent and smaller in size than in male sexual partners of women with CIN. <i>International Journal of Cancer</i> , 2005, 113, 36-41.	5.1	48

#	ARTICLE	IF	CITATIONS
199	Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. <i>International Journal of Cancer</i> , 2005, 113, 1005-1009.	5.1	120
200	Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. <i>International Journal of Cancer</i> , 2005, 115, 268-275.	5.1	35
201	HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. <i>International Journal of Cancer</i> , 2005, 115, 329-332.	5.1	59
202	Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: Proposal for new guidelines. <i>International Journal of Cancer</i> , 2005, 116, 122-129.	5.1	34
203	Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. <i>International Journal of Cancer</i> , 2005, 117, 177-181.	5.1	50
204	Concordance of Specific Human Papillomavirus Types in Sex Partners Is More Prevalent than Would Be Expected by Chance and Is Associated with Increased Viral Loads. <i>Clinical Infectious Diseases</i> , 2005, 41, 612-620.	5.8	112
205	Acquisition and Persistence of Human Papillomavirus Infection in Younger Men: A Prospective Follow-up Study among Danish Soldiers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1528-1533.	2.5	130
206	HPV-mediated transformation of the anogenital tract. <i>Journal of Clinical Virology</i> , 2005, 32, 25-33.	3.1	130
207	HPV DNA Detection and Typing in Cervical Scrapes. , 2005, 119, 101-114.		36
208	TSLC1 Gene Silencing in Cervical Cancer Cell Lines and Cervical Neoplasia. <i>Journal of the National Cancer Institute</i> , 2004, 96, 294-305.	6.3	194
209	Genetic Patterns in Head and Neck Cancers That Contain or Lack Transcriptionally Active Human Papillomavirus. <i>Journal of the National Cancer Institute</i> , 2004, 96, 998-1006.	6.3	378
210	POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women. <i>International Journal of Cancer</i> , 2004, 110, 94-101.	5.1	230
211	Against which human papillomavirus types shall we vaccinate and screen? the international perspective. <i>International Journal of Cancer</i> , 2004, 111, 278-285.	5.1	912
212	Tobacco, condom use and regression of CIN lesions. <i>International Journal of Cancer</i> , 2004, 112, 165-165.	5.1	0
213	Profiling of Caspase Signaling Pathways Predicts Clinical Response to Chemotherapy in Diffuse Large B-Cell Lymphomas.. <i>Blood</i> , 2004, 104, 1544-1544.	1.4	0
214	HPV Typing Comparison of Different Molecular Assays. , 2004, , 640-645.		0
215	HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. <i>Gynecologic Oncology</i> , 2003, 91, 67-73.	1.4	63
216	Telomerase activity in high-grade cervical lesions is associated with allelic imbalance at 6Q14-22. <i>International Journal of Cancer</i> , 2003, 105, 577-582.	5.1	16

#	ARTICLE	IF	CITATIONS
217	Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case-control study. <i>International Journal of Cancer</i> , 2003, 107, 127-133.	5.1	126
218	IL-1B promoter polymorphism and Epstein-Barr virus in Dutch patients with gastric carcinoma. <i>International Journal of Cancer</i> , 2003, 107, 866-867.	5.1	19
219	Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2003, 107, 804-810.	5.1	98
220	Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial. <i>International Journal of Cancer</i> , 2003, 107, 811-816.	5.1	171
221	ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects-a review. <i>Journal of Pathology</i> , 2003, 200, 4-15.	4.5	103
222	Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. <i>Journal of Pathology</i> , 2003, 201, 109-118.	4.5	145
223	The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. <i>Journal of Pathology</i> , 2003, 201, 1-6.	4.5	232
224	The presence of high-risk HPV combined with specific p53 and p16 ^{INK4a} expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma <i>in situ</i> and adenocarcinoma of the cervix. <i>Journal of Pathology</i> , 2003, 201, 535-543.	4.5	133
225	Pearly penile papules: Still no reason for uneasiness. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 50-54.	1.2	22
226	Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 518-527.	27.0	5,264
227	Human Papillomavirus and Oral Cancer: The International Agency for Research on Cancer Multicenter Study. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1772-1783.	6.3	1,013
228	GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes. <i>Journal of Clinical Microbiology</i> , 2002, 40, 779-787.	3.9	484
229	Role of Epstein-Barr Virus DNA Load Monitoring in Prevention and Early Detection of Post-transplant Lymphoproliferative Disease. <i>Leukemia and Lymphoma</i> , 2002, 43, 831-840.	1.3	97
230	High numbers of active caspase 3 ⁺ positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome. <i>Blood</i> , 2002, 100, 36-42.	1.4	42
231	Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?. <i>Blood</i> , 2002, 99, 232-237.	1.4	138
232	Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. <i>Blood</i> , 2002, 99, 4540-4546.	1.4	118
233	Down-Regulation of GATA-3 Expression during Human Papillomavirus-Mediated Immortalization and Cervical Carcinogenesis. <i>American Journal of Pathology</i> , 2002, 160, 1945-1951.	3.8	39
234	Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 351-357.	1.2	88

#	ARTICLE	IF	CITATIONS
235	Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance. <i>International Journal of Cancer</i> , 2002, 98, 590-595.	5.1	219
236	Apoptosis in B-cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method. <i>Journal of Pathology</i> , 2002, 196, 307-315.	4.5	32
237	Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners. <i>New England Journal of Medicine</i> , 2002, 346, 1105-1112.	27.0	707
238	Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. <i>Lancet, The</i> , 2001, 358, 1782-1783.	13.7	210
239	The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. <i>British Journal of Haematology</i> , 2001, 112, 950-958.	2.5	200
240	Pathologic analysis of sentinel lymph nodes. <i>Journal of Surgical Oncology</i> , 2001, 20, 238-245.	1.4	47
241	Absence of p16 expression in human gastric mucosa and carcinoma. <i>Journal of Pathology</i> , 2001, 194, 428-435.	4.5	31
242	High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. <i>Journal of Pathology</i> , 2001, 195, 300-306.	4.5	72
243	Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. <i>International Journal of Cancer</i> , 2001, 93, 232-235.	5.1	277
244	Differential expression of human Polycomb group proteins in various tissues and cell types. <i>Journal of Cellular Biochemistry</i> , 2001, 81, 129-143.	2.6	49
245	Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. <i>Cancer Gene Therapy</i> , 2001, 8, 342-351.	4.6	71
246	Telomerase Suppression by Chromosome 6 in a Human Papillomavirus Type 16-Immortalized Keratinocyte Cell Line and in a Cervical Cancer Cell Line. <i>Journal of the National Cancer Institute</i> , 2001, 93, 865-872.	6.3	67
247	High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. <i>Journal of Pathology</i> , 2001, 195, 300-306.	4.5	3
248	No direct role for Epstein-Barr virus in oral carcinogenesis: A study at the DNA, RNA and protein levels. , 2000, 86, 356-361.		42
249	p53 immunoreexpression in non-malignant oral mucosa adjacent to oral squamous cell carcinoma: potential consequences for clinical management. , 2000, 191, 132-137.		34
250	Epstein-Barr virus is present in neoplastic cytotoxic T cells in extranodal, and predominantly in B cells in nodal T non-Hodgkin lymphomas. <i>Journal of Pathology</i> , 2000, 191, 400-406.	4.5	26
251	Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types. <i>International Journal of Cancer</i> , 2000, 87, 221-227.	5.1	243
252	Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. <i>International Journal of Cancer</i> , 2000, 88, 92-98.	5.1	79

#	ARTICLE	IF	CITATIONS
253	Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients?. <i>Annals of Neurology</i> , 2000, 48, 399-399.	5.3	20
254	Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. <i>Blood</i> , 2000, 95, 3653-3661.	1.4	741
255	Squamous Cell Carcinoma of the Penis: Premalignant Lesions. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 187-188.	1.4	27
256	Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types. <i>International Journal of Cancer</i> , 2000, 87, 221-227.	5.1	3
257	Adverse Effects of Activated Cytotoxic T Lymphocytes on the Clinical Outcome of Nodal Anaplastic Large Cell Lymphoma. <i>Blood</i> , 1999, 93, 2688-2696.	1.4	51
258	Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. <i>Journal of Pathology</i> , 1999, 189, 12-19.	4.5	7,095
259	Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. <i>Lancet</i> , The, 1999, 354, 20-25.	13.7	627
260	Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. , 1999, 189, 12.		39
261	Mailed, Home-Obtained Urine Specimens: a Reliable Screening Approach for Detecting Asymptomatic <i>Chlamydia trachomatis</i> Infections. <i>Journal of Clinical Microbiology</i> , 1999, 37, 976-980.	3.9	73
262	Monitoring of Epstein-Barr Virus DNA Load in Peripheral Blood by Quantitative Competitive PCR. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2852-2857.	3.9	111
263	Risk factors for HPV infection in women from sexually transmitted disease clinics: Comparison between two areas with different cervical cancer incidence. , 1998, 75, 1-8.		49
264	Non-random allelic losses at 3p, 11p and 13q during HPV-mediated immortalization and concomitant loss of terminal differentiation of human keratinocytes. , 1998, 76, 412-417.		31
265	Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women. , 1998, 76, 613-619.		53
266	Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women. <i>International Journal of Cancer</i> , 1998, 76, 613-619.	5.1	5
267	Genotyping of <i>Chlamydia trachomatis</i> in Urine Specimens Will Facilitate Large Epidemiological Studies. <i>Journal of Clinical Microbiology</i> , 1998, 36, 3077-3078.	3.9	38
268	Viral E6-E7 Transcription in the Basal Layer of Organotypic Cultures without Apparent p21cip1 Protein Precedes Immortalization of Human Papillomavirus Type 16- and 18-Transfected Human Keratinocytes. <i>Journal of Virology</i> , 1998, 72, 749-757.	3.4	47
269	Sexually Transmitted Infection as a Cause of Anal Cancer. <i>New England Journal of Medicine</i> , 1997, 337, 1350-1358.	27.0	635
270	Seroreactivity to Human Papillomavirus Type 16 Virus-like Particles Is Lower in High-Risk Men than in High-Risk Women. <i>Journal of Infectious Diseases</i> , 1997, 176, 876-883.	4.0	63

#	ARTICLE	IF	CITATIONS
271	Most Primary Cutaneous CD30-Positive Lymphoproliferative Disorders Have a CD4-Positive Cytotoxic T-Cell Phenotype. <i>Journal of Investigative Dermatology</i> , 1997, 109, 636-640.	0.7	131
272	Do HPV-negative cervical carcinomas exist?. , 1997, 181, 253-254.		125
273	Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinomas of the head and neck. , 1996, 66, 464-469.		110
274	The presence of persistent high-risk hpv genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. <i>International Journal of Cancer</i> , 1995, 61, 306-311.	5.1	344
275	The expression pattern of contractile and intermediate filament proteins in developing skeletal muscle and rhabdomyosarcoma of childhood: Diagnostic and prognostic utility. <i>Journal of Pathology</i> , 1994, 174, 283-292.	4.5	28
276	Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. <i>International Journal of Cancer</i> , 1994, 56, 802-806.	5.1	98
277	Noncutaneous T-cell lymphomas recognition of a lymphoma type (large cell anaplastic) with a relatively favorable prognosis. <i>Cancer</i> , 1993, 71, 2604-2612.	4.1	21
278	Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is ageâ€dependent. <i>International Journal of Cancer</i> , 1993, 53, 919-923.	5.1	242
279	Large cell lymphomas. I. Differential diagnosis of centroblastic and b-immunoblastic subtypes by morphometry on histologic preparations. <i>Cancer</i> , 1984, 54, 2082-2087.	4.1	31
280	Evaluation of <i>FAM19A4/miR124â€2</i> methylation performance in the management of <sc>CIN3</sc> diagnosed pregnant women. <i>International Journal of Cancer</i> , 0, , .	5.1	4